Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, +19

Journal of Clinical Oncology

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

Miyako Satouchi, Shunichi Negoro, Yasuhiro Funada, +10

British Journal of Cancer

Tobacco ControlOncologyCancer RiskPredictive FactorsEpidemiology Of Cancer +12

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trial

Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, +17

Cancer

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Motoko Tachihara, Shunichi Negoro, Takako Inoue, +8

BMC Cancer

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

Yuichiro Yasuda, Yoshiko Urata, Rie Tohnai, +8

Internal Medicine

Immune-related Colitis InducedDysbiosisLung InflammationImmunologyGastroenterology +15

The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease

Yuichiro Yasuda, Yoshihiro Hattori, Rie Tohnai, +8

Japanese Journal of Clinical Oncology

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Tomoyuki Otsuka, Masahide Mori, Yukihiro Yano, +13

PubMed

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, +13

Lung Cancer

MedicinePathologyBronchial NeoplasmImmune Checkpoint InhibitorCancer Treatment +5

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)

Kazumi Nishino, Fumio Imamura, Toru Kumagai, +12

Lung Cancer

MedicineMetronomic TherapyClinical TrialsPathologyBronchial Neoplasm +5

EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403)

Isamu Okamoto, Tatsuhiko Kashii, Yoshiko Urata, +7

Journal of Clinical Oncology

Single-agent GefitinibMedicineCancer ManagementMetronomic TherapyPathology +10